Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of the Board meeting held on July 23, 2025.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals reported strong Q1 FY26 (quarter ended June 30, 2025) results. Consolidated total income jumped 72% year-on-year to Rs. 141.35 crore (from Rs. 80.87 crore in Q1 FY25), while net profit surged 95% YoY to Rs. 21.18 crore (from Rs. 10.91 crore). EBITDA rose 60% YoY to Rs. 34.2 crore, with EBITDA margin expanding to 24.8% and PAT margin at 15.4%. Regulated Markets revenue grew 69% YoY to Rs. 90 crore, and Emerging Markets revenue rose 32% YoY to Rs. 29 crore. The company launched 2 own ANDA products and received 4 ANDA approvals during the quarter. Additionally, the Board categorized Mr. Jignesh Shashikant Desai (President-Finance, 30+ years of experience) as Senior Management Personnel effective July 23, 2025. Of the Rs. 500 crore IPO proceeds raised in December 2024, Rs. 240.99 crore has been utilized as of June 30, 2025, with Rs. 259.01 crore still unutilized.
A near-doubling of profits and broad-based revenue growth across both Regulated and Emerging Markets reflect strong operating momentum and is likely to be viewed positively by investors. The healthy cash flow and scaling CDMO/CMO segment provide good visibility, while unutilized IPO funds earmarked for capacity expansion and acquisitions could act as future growth catalysts.